Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Monday. The firm set a “sell” rating on the basic materials company’s stock.

Several other analysts have also weighed in on the company. Lake Street Capital upgraded Arcadia Biosciences to a “strong-buy” rating in a research report on Tuesday, May 14th. HC Wainwright lowered their price objective on shares of Arcadia Biosciences from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, May 23rd.

Arcadia Biosciences Trading Down 4.3 %

Shares of RKDA opened at $2.65 on Monday. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $4.79. The firm has a market capitalization of $3.60 million, a P/E ratio of -0.51 and a beta of 0.86. The firm’s 50-day moving average is $2.95 and its two-hundred day moving average is $2.64.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 56.06% and a negative net margin of 127.29%. The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the firm earned ($2.64) EPS. Analysts predict that Arcadia Biosciences will post -2.29 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.